Author + information
Urocortin 2 (Ucn 2) and urocortin 3 (Ucn 3) have an emerging role in the pathophysiology and treatment of heart failure in man. We examined the effect of Ucn 2 and Ucn 3 in patients with heart failure using an in vivo human forearm arterial model.
Eight patients with stable heart failure (NYHA II-IV; 59±8 years) and eight age and sex-matched healthy volunteers (59±8 years) underwent bilateral forearm venous occlusion plethysmography during incremental intra-arterial infusions of Ucn 2 (3.6-36 pmol/min), Ucn 3 (360-3600 pmol/min) and substance P (2-8 pmol/min). The order of infusion of Ucn 2, Ucn 3 and Sub P was randomised between subjects.
There were no differences in forearm vasodilatation in response to ucn 2, ucn 3 and substance P between the two groups (P>0.05 for all three peptides). At the highest dose infused, Ucn 3 induced a transient tachycardia (P<0.05) in both groups associated with a drop in diastolic blood pressure in healthy volunteers (P=0.02) suggesting systemic spillover from the infused forearm. However, non-infused forearm blood flow remained unchanged in both groups (P>0.05).
The vasodilator effects of Ucn 2 and Ucn 3 are preserved in patients with heart failure and hold potential therapeutic promise for the treatment of acute or chronic heart failure.
Poster Sessions, Expo North
Saturday, March 09, 2013, 3:45 p.m.-4:30 p.m.
Session Title: Novel Therapeutic Targets in Hearts Failure
Abstract Category: 16. Heart Failure: Basic
Presentation Number: 1176-298
- 2013 American College of Cardiology Foundation